Find Clinical Trial
An open label, multicentre, positron emission tomography (PET) imaging study using Zirconium-89 to investigate the biodistribution and tumour uptake of a PD-L1x4-1BB bispecific antibody (S095012) in patients with advanced solid tumours
← Back
| Study Phase |
Phase 1 |
| Therapeutic Area |
Cancers |
| Indication | Solid tumors |
| Sponsor | IRIS |
| Active substance/ Medical device |
"S095012" |
| Active Substance Code | S095012 |
| Protocol Code | CL1-95012-002 |
| EudraCT Code | 2021‐001764‐20 |
| NCT Code | NCT05638334 |
Documents and links
| Results are not yet available. |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
